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asses of the Heart:
erfusing the “Good”
rom the Bad*
lyse Foster, MD, FACC,
vor L. Gerber, MBCHB, FRACP
an Francisco, California
n 1951, the feeling of frustration regarding the inadequacy
f the antemortem diagnosis of cardiac masses was summa-
ized by Pritchard (1) in a review of tumors of the heart:
Tumors of the heart are rarely diagnosed before autopsy.
urgical treatment of these neoplasms is virtually unheard
f, and the present state of diagnosis is far behind the
herapeutic possibilities. Several authors have wholeheart-
dly subscribed to the view that the diagnosis of cardiac
umors is either impossible or a matter of chance. Seen from
he threshold of an era of ever bolder cardiac surgery, these
umors present a dismal diagnostic prospect.” Considerable
See page 1412
rogress in cardiac imaging modalities over the past 50 years
as resulted in an improved understanding of the prevalence
nd natural history of various cardiac masses, and advances
n surgery have enabled resection of most cardiac tumors.
chocardiography is the most widely used application in the
nitial investigation of cardiac masses. However, a major
imitation of all current imaging modalities is their inability
o accurately distinguish thrombus from benign and malig-
ant tumors. This distinction has major therapeutic impli-
ations.
Before the advent of transthoracic echocardiography
TTE), the means of detecting cardiac masses were limited
o angiography or direct inspection at surgery or postmor-
em. Early M-mode studies were able to detect intracardiac
asses as small as 1 mm. Two-dimensional echocardiogra-
hy made it possible to define the spatial extent, structural
elationships, and mobility of both intracardiac and extra-
ardiac masses (2). Although TTE is useful in the initial
valuation of cardiac masses, transesophageal echocardiog-
aphy (TEE) frequently is required for a more comprehen-
ive and accurate assessment, especially for the visualization
f masses within the atria and the atrial appendages or those
ssociated with the heart valves (3). Transesophageal echo-
ardiography is particularly important in detecting smaller
asses not seen on TTE. Features that aid in formulating a
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, Division of Cardiology, University of Califor-aia San Francisco, San Francisco, California.ifferential diagnosis of a mass include location, size, shape,
texture,” mobility, sites of attachment, and the presence or
bsence of myocardial infiltration. Unfortunately, the accu-
acy of the echocardiographic characterization is less than
deal, and the use of echocardiography provides only an
educated guess” as to the diagnosis. Moreover, both TTE
nd TEE are limited in evaluating masses in the mediasti-
um and paracardiac structures. Magnetic resonance imag-
ng (MRI) has proved to be the gold standard for the
ssessment of these masses (4). However, the widespread
vailability, portability, and additional functional informa-
ion provided by echocardiography makes it the initial
nvestigation of choice for the assessment of cardiac masses.
Recent advances in echocardiographic imaging include
ontrast-enhanced imaging and power modulation (5,6). At
resent, the major clinical indication for contrast-enhanced
chocardiography is endocardial border delineation for the
valuation of global and segmental left ventricular (LV)
unction. Emerging applications include the evaluation of
yocardial perfusion and the improvement of the definition
f intracavitary structures (7). In this issue of the Journal,
irkpatrick et al. (8) have extended the use of contrast-
nhanced imaging to determine the relative perfusion of
ardiac masses and thereby aid in the differentiation of the
parse vascularity of a benign tumor, neovascularization of a
alignancy or vascular tumor, and an avascular thrombus.
lthough the number of patients in the study was small (n
16), the addition of contrast perfusion imaging enabled
he correct diagnosis to be made by a single experienced
bserver in all cases and improved the diagnostic accuracy of
ess experienced observers compared with the pathological
iagnosis.
A number of limitations of the Kirkpatrick et al. (8) study
eed to be considered. No clinical data were provided by the
uthors. The most likely diagnosis of a cardiac mass can
ften be made by a combination of the echocardiographic
ppearance and location of the mass together with clinical
ata. For example, 7 of the 16 cardiac masses, including 5 of
he 6 masses located in the LV apex, were intracardiac
hrombi, reflecting the relatively high incidence of intracar-
iac thrombus compared with cardiac tumors. Although in
istinction to the malignant masses the thrombi failed to
nhance with contrast, it is likely that the clinical setting
ay have substantially aided the diagnosis without the need
or contrast. Left ventricular thrombi typically occur in
onditions associated with stasis of blood flow and/or
egional wall motion abnormalities, including myocardial
nfarction (especially the cardiac apex), LV aneurysm, and
ilated cardiomyopathy (2,9). A history of a myocardial
nfarction and/or apical wall motion abnormality on echo-
ardiography would make the diagnosis of an apical mass far
ore likely to be a thrombus than the much rarer tumor. In
upport of the use of contrast, LV thrombi have been
eported in patients with normal regional LV function, and
lthough there are other distinguishing echocardiographic
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April 21, 2004:1420–2 Editorial Commentharacteristics of LV thrombus, these features may be
ariably present (9). Both left atrial masses were myxomas.
limitation of the use of contrast for differentiating
hrombus from myxoma was pointed out by the authors:
hereas myxomas appeared to demonstrate partial enhance-
ent to visual inspection, thrombi and myxomas could not
e differentiated objectively on the basis of average pixel
ntensity in the mass relative to the myocardium. As for LV
asses, the clinical setting usually aids in the distinction of
hrombus from myxoma in the left atrium. For example, left
trial thrombi typically occur in patients with a clinical
ondition associated with stasis of blood in the left atrium
uch as atrial fibrillation, mitral stenosis, prosthetic mitral
alve, left atrial enlargement, and low cardiac output (9). A
urther distinctive feature is that compared with myxomas
hat are typically (but not always) attached to the fossa ovalis
y a narrow stalk, left atrial thrombi tend to have a
road-based attachment to the posterior and lateral walls,
specially within the left atrial appendage (2).
Of the 16 patients in the study by Kirkpatrick et al. (8),
patients had a mass in the pericardium, all of which were
etastatic adenocarcinomas. The major differential diagno-
is of a pericardial mass is a primary tumor versus metastatic
isease (10). Metastatic tumors to the heart and pericardium
ccur in up to 15% of patients with malignant diseases and
re 20 to 40 times more common than primary tumors (11).
arcinomas of the lungs and breast, because of their
revalence, are the most common malignant tumors that
etastasize to the heart, whereas melanoma has the greatest
ropensity to metastasize to the heart (11). Cardiac metas-
ases generally appear late in the course of the primary
isease, and isolated cardiac involvement is rarely seen
ithout dissemination to other organs or as the presenting
ymptom of a remote primary tumor (2). Nearly all primary
alignant cardiac tumors are sarcomas, and angiosarcoma is
he most frequent. Because angiosarcomas tend to occur in
he right atrium and involve the pericardium, the most
requent clinical presentation is right-sided heart failure or
amponade (10). Operative intervention is usually unsuc-
essful, and the prognosis is poor (11). In the study by
irkpatrick et al. (8), five masses were located in right-sided
ardiac chambers: three were malignant and two were
hrombi. Most tumors arising within the right atrium are
enign (most commonly myxomas, lipomas, hemangiomas,
nd thrombi), whereas those extending into the right atrium
rom outside are malignant (most commonly hypernephroma,
epatoma, and uterine leiomyosarcoma). Right ventricular
umors are rare and when encountered are likely to be from a
etastatic malignancy (12).
Magnetic resonance imaging has been a major advance in
he assessment of cardiac masses. A recent article on the
sefulness of MRI of cardiac and paracardiac masses con-
luded that there was no single feature that was both highly
pecific and highly sensitive for malignant tumors (13).
ighly sensitive but less specific for malignant lesions werehe location outside the left heart, inhomogeneity, andadolinium enhancement. The specificity of gadolinium
nhancement for malignancy increased when only moderate
nd strong enhancement were considered because mild
nhancement was found in 8 of 19 benign tumors. Highly
pecific but less sensitive indicators for malignant lesions
ere the infiltration of adjacent compartments, tumor size
5 cm, and the presence of pericardial and/or pleural
ffusions. All inhomogeneous tumors located in the right
eart with concurrent pericardial effusion were malignant,
hereas homogeneous tumors located in the left heart
ithout pericardial effusion were always benign.
Although advances in contrast-enhanced imaging may
mprove the distinction of thrombus and benign and ma-
ignant masses, they cannot provide a histological diagnosis
hat may present important information on prognosis and
ppropriate therapy. Transvenous biopsy of masses in the
ight heart has been performed with success and may guide
urther investigations and management, but it is not rou-
inely performed for the more common left heart and
ericardial masses (12). Future clinical applications for
ontrast-enhanced echocardiography will likely expand be-
ond perfusion imaging. There has been considerable
rogress in the past few years in the development of
ite-targeted microbubbles that attach to specific markers of
isease, allowing noninvasive diagnostic ultrasound imaging
f molecular and cellular processes (14). Similar targeting of
icrobubbles to tumor antigens may provide a useful
ethod for diagnosing neoplasms with ultrasound, for
etecting metastases, and for characterizing tumor pheno-
ype (14). It has recently been shown that contrast-
nhanced ultrasound with microbubbles targeted to markers
n neovascular endothelium can noninvasively detect early
umor angiogenesis (15). Further investigations are needed
o determine whether targeted imaging of angiogenic phe-
otype in different tumor types provides additional diagnos-
ic and prognostic information to imaging methods already
sed in the clinical setting. The use of microbubbles and
ltrasound for therapeutic purposes is also now being
ealized with the potential for both the accurate diagnosis
nd therapeutic intervention of cardiac masses (14). The
pecific role for contrast echocardiography in the diagnosis
f cardiac and pericardial tumors will await further studies
hat include larger numbers of patients and comparison with
RI. Nonetheless, the study by Kirkpatrick et al. (8)
rovides clinicians with another tool to use in the preoper-
tive diagnosis of cardiac masses.
eprint requests and correspondence: Dr. Elyse Foster, Profes-
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